348 related articles for article (PubMed ID: 37160786)
41. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
42. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
43. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
[TBL] [Abstract][Full Text] [Related]
44. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
[TBL] [Abstract][Full Text] [Related]
45. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J; Hyötyläinen T; Orešič M; Nyström T
Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
[TBL] [Abstract][Full Text] [Related]
46. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
47. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
48. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
49. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
50. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
51. [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
Sklyanik IA; Shestakova MV
Ter Arkh; 2021 Oct; 93(10):1203-1208. PubMed ID: 36286822
[TBL] [Abstract][Full Text] [Related]
52. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
53. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY; Qu XN; Sun ZY; Zhang Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
[TBL] [Abstract][Full Text] [Related]
54. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q; Jia M; Yan Z; Li Q; Sun F; He C; Li Y; Zhou X; Zhang H; Liu X; Bu X; Gao P; He H; Zhao Z; Zhu Z
J Am Heart Assoc; 2021 Jul; 10(14):e020734. PubMed ID: 34250817
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB; Renström F; Aczél S; Folie P; Biraima-Steinemann M; Beuschlein F; Bilz S
Obes Surg; 2023 Apr; 33(4):1017-1025. PubMed ID: 36765019
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Diaz Soto G; Izaola O; Romero E
J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
[TBL] [Abstract][Full Text] [Related]
57. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
58. Long-term effectiveness and safety of liraglutide in clinical practice.
Ponzani P
Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
[TBL] [Abstract][Full Text] [Related]
59. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
Svane MS; Johannesen HH; Hansen AE; Martinussen C; Bojsen-Møller KN; Hansen ML; Deacon CF; Keller SH; Klausen TL; Loft A; Kjaer A; Löfgren J; Madsbad S; Holst JJ; Wewer Albrechtsen NJ
Int J Obes (Lond); 2022 Nov; 46(11):2058-2062. PubMed ID: 35982119
[TBL] [Abstract][Full Text] [Related]
60. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
